- /
- Supported exchanges
- / US
- / RHHBY.OTCQX
Roche Holding Ltd ADR (RHHBY OTCQX) stock market data APIs
Roche Holding Ltd ADR Financial Data Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Roche Holding Ltd ADR (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Roche Holding Ltd ADR data using free add-ons & libraries
Get Roche Holding Ltd ADR Fundamental Data
Roche Holding Ltd ADR Fundamental data includes:
- Net Revenue: 63 356 M
- EBITDA: 24 044 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-23
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding Ltd ADR News
New
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
Halozyme Therapeutics HALO reported first-quarter 2026 adjusted earnings of $1.60 per share, which beat the Zacks Consensus Estimate of $1.54. Earnings rose 44.1% year over year. Total revenues in th...
Nucleic Acid Isolation and Purification Market Report 2026-2030: Trends, Challenges and Competitive Analysis Featuring Thermo Fisher Scientific, Merck, QIAGEN, and Roche
Company Logo Nucleic Acid Isolation and Purification MarketNucleic Acid Isolation and Purification Market·GlobeNewswire Inc. Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Nucleic Acid Isolation and...
BanyanGlobal Names Stephan Roche Managing Partner
Former Walton Family Enterprises CEO and Cascade executive to lead firm’s next chapter BOSTON, May 12, 2026--(BUSINESS WIRE)--BanyanGlobal Family Business Advisors today announced that partner Step...
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics, Inc. Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combin...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.